ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.
ETFOptimize | HOME
Close Window
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

The SCIEX 7500+ System Launches at ASMS 2024

By: via Business Wire

At ASMS 2024, SCIEX, a global leader in life science analytical technologies, launches the SCIEX 7500+ system, the newest mass spectrometer in the SCIEX quantitative portfolio, building upon a legacy of reliable, sensitive quantitation. While sensitivity is critical to solve the most impactful analytical challenges, scientists are under pressure to meet deadlines faster and to quantify from increasingly various and complex sample types. The SCIEX 7500+ system delivers both sensitivity and resilience when scientists need it most.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240603002122/en/

The SCIEX 7500+ system (Photo: Business Wire)

The SCIEX 7500+ system (Photo: Business Wire)

The SCIEX 7500+ system offers increased resilience across a large suite of sample types and workflows, and improved user-serviceability.

     

-

Mass Guard technology is a new proprietary technology that includes the ability to actively filters out potentially contaminating ions. It reduces the risk and frequency of instrument contamination, helping to maintain the highest sensitivity for up to 2X as long compared to existing SCIEX technology, particularly when running complex matrices.

     

-

DJet+ assembly is fully removable, allowing front-end serviceability so customers can maximize the uptime of their systems.

     

-

At 800 MRM per second, the SCIEX 7500+ system is the fastest SCIEX Triple Quad to date. This increases the scope for large quantitation panels that need to incorporate new compounds of interest, improving the overall productivity of the lab.

     

-

Supported by new functionality in SCIEX OS that allows users to track instrument performance and automate decision making, reducing the potential for failed batches and repeat measurements.

     

-

Compatibility with dry roughing pumps can reduce electricity consumption by 24% relative to oil-sealed pumps.

“Over the years, we have worked with experts in the field and innovated various breakthrough quantitative solutions. We have seen demand increase for testing on more and more sample types at high sensitivity. The SCIEX 7500+ system meets these needs by ensuring the highest performance can be maintained for longer and across these increasingly complex matrices,” said Joe Fox, President at SCIEX.

Learn more about the SCIEX 7500+ system by visiting www.sciex.com/7500plus.

About SCIEX

SCIEX empowers our customers to solve the most impactful analytical challenges in quantitation and characterization. With groundbreaking innovation and outstanding reliability and support, SCIEX has been at the forefront of the field for over 50 years. ​

Since the launch of the first-ever commercially successful triple quadrupole in 1981, we continue to develop technologies and solutions that influence life-changing research and outcomes. That’s why thousands of life science experts around the world choose SCIEX to get the answers they can trust. ​

Advances in human wellness depend on the power of precise science.​

For more information, visit sciex.com. ​

Connect with us on LinkedIn, Facebook, X (Twitter) and Instagram.​

SCIEX is proud to be part of Danaher. ​

Danaher’s science and technology leadership puts SCIEX solutions at the forefront of the industry, so they can reach more people. Being part of Danaher means we can offer unparalleled breadth and depth of expertise and solutions to our customers. Together with Danaher’s other businesses across Biotechnology, Diagnostics and Life Sciences, we unlock the transformative potential of cutting-edge science and technology to improve billions of lives every day.

The SCIEX clinical diagnostic portfolio is For In Vitro Diagnostic Use. Rx Only. Product(s) not available in all countries. For information on availability, please contact your local sales representative or refer to www.sciex.com/diagnostics. All other products are For Research Use Only. Not for use in Diagnostic Procedures.

Trademarks and/or registered trademarks mentioned herein, including associated logos, are the property of AB Sciex Pte. Ltd. or their respective owners in the United States and/or certain other countries (see www.sciex.com/trademarks).

© 2024 DH Tech. Dev. Pte. Ltd. MKT- 31792.

Contacts

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.


 
IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.